Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415 525 4200

Website: www.nurixtx.com

Address:

1700 Owens Street, Suite 205, San Francisco, United States

JFais Dec. 12 at 3:26 PM

$NRIX- nice run up so far to $19

0 · Reply

LongTrainRunning Dec. 10 at 4:18 PM

$NRIX I’m bullish long-tern but I’m betting that we drop significantly between now and EHA in June because we’ll be in a catalyst vacuum without much buyer support. That’s why I sold a good amount on Monday when we jumped on ASH news. I want to buy back between now and EHA. Who wants to guess how low we’ll go during that period and when the low will be? I think we might see $14 in March. If you have a different projection for the next six months let’s hear it.

3 · Reply

JarvisFlow Dec. 10 at 2:40 PM

Mizuho updates rating for Nurix Therapeutics ( $NRIX ) to Outperform, target set at 24 → 30.

0 · Reply

JarvisFlow Dec. 10 at 12:42 PM

HC Wainwright & Co. has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 31.

0 · Reply

JarvisFlow Dec. 9 at 6:52 PM

BTIG has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 30.

0 · Reply

LongTrainRunning Dec. 9 at 1:05 AM

$NRIX presentation tonight at 8:15pm EST https://ir.nurixtx.com/events/event-details/webcast-discuss-data-presented-64th-american-society-hematology-ash-annual-0

1 · Reply

Hugo_HoldnFlip Dec. 8 at 8:54 PM

$NRIX underfollowed biotech, asymmetry is the appeal with disciplined risk

0 · Reply

ChazzyTrades Dec. 8 at 6:18 PM

$NRIX 🚀🚀

0 · Reply

notreload_ai Dec. 8 at 5:24 PM

$NRIX presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients. https://notreload.xyz/nurix-shows-strong-phase-1-results-for-bexobrutideg/

0 · Reply

RonIsWrong Dec. 8 at 4:14 PM

$NRIX very nice, @Wigglyick ! I took profits this morning on this move. Great run in less than 1 month. Grazie!

1 · Reply

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript

Dec 8, 2025, 8:00 AM EST - 5 days ago

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

$Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition$

Dec 6, 2025, 9:30 AM EST - 7 days ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec 1, 2025, 7:00 AM EST - 12 days ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 25, 2025, 7:00 AM EST - 18 days ago

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 4 weeks ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov 7, 2025, 9:00 AM EST - 5 weeks ago

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov 3, 2025, 9:00 AM EST - 5 weeks ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 30, 2025, 7:00 AM EDT - 6 weeks ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 27, 2025, 7:00 AM EDT - 6 weeks ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Oct 22, 2025, 6:53 PM EDT - 7 weeks ago

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript

Oct 22, 2025, 7:20 AM EDT - 7 weeks ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

$Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia$

Oct 22, 2025, 6:00 AM EDT - 7 weeks ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Oct 18, 2025, 3:00 AM EDT - 2 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Oct 11, 2025, 8:13 AM EDT - 2 months ago

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Oct 9, 2025, 4:01 PM EDT - 2 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Sep 17, 2025, 7:00 AM EDT - 3 months ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Sep 12, 2025, 9:56 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 12, 2025, 9:43 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Sep 11, 2025, 3:14 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 10, 2025, 9:42 AM EDT - 3 months ago

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Jul 13, 2025, 8:30 AM EDT - 5 months ago

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 9, 2025, 4:01 PM EDT - 5 months ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 5 months ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 6 months ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 6 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 2, 2025, 7:00 AM EDT - 6 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 7 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 7 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 5:07 PM EDT - 8 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 7:00 AM EDT - 8 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 9 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 9 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 9 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Feb 4, 2025, 7:00 AM EST - 11 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 11 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 11 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 9, 2025, 8:44 AM EST - 1 year ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 6, 2025, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia$

Dec 19, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 9, 2024, 6:00 PM EST - 1 year ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2024, 7:00 AM EST - 1 year ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

$Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia$

Nov 20, 2024, 4:00 PM EST - 1 year ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

JFais Dec. 12 at 3:26 PM

$NRIX- nice run up so far to $19

0 · Reply

LongTrainRunning Dec. 10 at 4:18 PM

3 · Reply

JarvisFlow Dec. 10 at 2:40 PM

Mizuho updates rating for Nurix Therapeutics ( $NRIX ) to Outperform, target set at 24 → 30.

0 · Reply

JarvisFlow Dec. 10 at 12:42 PM

HC Wainwright & Co. has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 31.

0 · Reply

JarvisFlow Dec. 9 at 6:52 PM

BTIG has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 30.

0 · Reply

LongTrainRunning Dec. 9 at 1:05 AM

$NRIX presentation tonight at 8:15pm EST https://ir.nurixtx.com/events/event-details/webcast-discuss-data-presented-64th-american-society-hematology-ash-annual-0

1 · Reply

Hugo_HoldnFlip Dec. 8 at 8:54 PM

$NRIX underfollowed biotech, asymmetry is the appeal with disciplined risk

0 · Reply

ChazzyTrades Dec. 8 at 6:18 PM

$NRIX 🚀🚀

0 · Reply

notreload_ai Dec. 8 at 5:24 PM

0 · Reply

RonIsWrong Dec. 8 at 4:14 PM

$NRIX very nice, @Wigglyick ! I took profits this morning on this move. Great run in less than 1 month. Grazie!

1 · Reply

mystocks111 Dec. 8 at 3:49 PM

$NRIX its going to pop like all these other ones

0 · Reply

topstockalerts Dec. 8 at 3:47 PM

$NRIX keep an eye for today..

0 · Reply

quodo Dec. 8 at 3:31 PM

$NRIX $DYN $CVNX $CORD looking strong. A good small-cap mover today — if you're scouting for the next one before the rotation hits, check $CAPS https://capstoneholdingcorp.com/news/

0 · Reply

quodo Dec. 8 at 2:55 PM

$CFLT $GPCR $NRIX $WVE Nice run today 👏 If you’re scanning for the next sleeper small cap, watch $CAPS — real revenue, tiny float, no dilution. https://capstoneholdingcorp.com/

0 · Reply

oaksapollo Dec. 8 at 2:52 PM

$NRIX I haven't been following Beigene's program carefully but sounds like bexo is differentiated by safety (not so much efficacy) @LongTrainRunning

0 · Reply

SlothMan2025 Dec. 8 at 2:42 PM

$CAPS is a unique chance to get in before institutions load up & flippers take it for a ride. The cheaper someone wants to sell shares, the more shares you get for the same amount of money. It's a win-win. I've got my bag, 213k. Anyone want to match me? 🤙 $NRIX $CFLT $FULC $KYMR

0 · Reply

quodo Dec. 8 at 2:41 PM

All these tickers exploding $NRIX $OCUL $GPCR $CETX and y’all ignoring the one with ACTUAL REVENUE: $CAPS is the only small cap not held together with PowerPoint slides. Don’t say i didn’t warn you. https://capstoneholdingcorp.com/

1 · Reply

JarvisFlow Dec. 8 at 2:37 PM

Needham has updated their rating for Nurix Therapeutics ( $NRIX ) to Buy with a price target of 26.

0 · Reply

quodo Dec. 8 at 2:35 PM

Nice moves today $NRIX $CFLT $FULC $KYMR. If you want the sleeper setup before it hits Top Gainers: $CAPS Real biz + tiny float + no dilution. A McLaren hiding in penny-stock clothing

0 · Reply

oaksapollo Dec. 8 at 2:35 PM

$NRIX Kymera is now worth 3 Nurix's. Or is it 3 Nurixes? Approaching $7B.

1 · Reply

topstockalerts Dec. 8 at 2:24 PM

$NRIX following closely 👀

0 · Reply

LongTrainRunning Dec. 8 at 2:07 PM

$NRIX Is anyone selling the news today? I wonder if we'll fade next year between catalysts and if so that could be a buying opportunity relative to today's price. But with this stock if you miss a handful of days you miss all of the gains.

2 · Reply

Market Cap	1.47B
Revenue (ttm)	54.55M
Net Income (ttm)	-193.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-354.85%
Debt to Equity Ratio	0.00

Volume	1,893,400
Avg Vol	1,793,098
Day's Range	N/A - N/A
Shares Out	76.88M
Stochastic %K	47%
Beta	1.87
Analysts	Strong Sell
Price Target	$27.39